Business Context and Reporting Period
This Form 8-K reports on the results of the 2020 Annual Meeting of Stockholders for SANUWAVE Health, Inc., held on July 23, 2020. The company is incorporated in Nevada and trades on the OTCQB under the symbol SNWV.
Key Financial Metrics
This filing is a current report regarding corporate governance and stockholder votes. It does not provide financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics.
Material Changes and Corporate Actions
Stockholders approved several significant corporate actions at the Annual Meeting:
- Reincorporation: Approved the move of the company's domicile from the State of Nevada to the State of Delaware.
- Capital Structure: Approved an amendment to increase authorized common stock by 250 million shares, bringing the total to 600 million shares.
- Reverse Stock Split Authorization: Authorized the Board of Directors to effect a reverse stock split of outstanding common stock at a ratio between 1-for-10 and 1-for-50, with the exact ratio to be determined by the Board.
- Director Elections: All six nominees (Kevin A. Richardson II, John F. Nemelka, Alan L. Rubino, A. Michael Stolarski, Maj-Britt Kaltoft, and Thomas Price) were elected to serve until the 2021 Annual Meeting.
- Auditor Ratification: Ratified the appointment of Marcum LLP as the independent registered public accounting firm for the fiscal year ended December 31, 2020.
Guidance, Outlook, and Management Commentary
The filing contains no financial guidance, outlook, or management commentary regarding future business performance. Regarding executive compensation, stockholders approved an advisory vote to hold such votes every three years. The next required advisory vote on the frequency of these votes will occur no later than the 2026 Annual Meeting.
Investor Verification Checklist
- Verify the specific reverse stock split ratio once determined by the Board of Directors.
- Confirm the completion of the reincorporation process from Nevada to Delaware.
- Review the definitive proxy statement (Schedule 14A) for details on executive compensation approved in Proposal 6.
- Monitor future filings for the implementation of the increased authorized share count.